Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 7.

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
HIV: THE GLOABAL AND INDIAN SCENARIO DR. KANUPRIYA CHATURVEDI DR. S.K CHATURVEDI.
1 Global AIDS Epidemic The first AIDS case was diagnosed in years later, 20 million people are dead and 37.8 million people (range: 34.6–42.3 million)
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
© Aahung 2004 Millennium Development Goals Expanding the Agenda:
Doing the Right Thing Karen A. Stanecki XV International AIDS Conference.
The HIV/AIDS Epidemic © 2005 John B. Pryor Illinois State University.
Slide 2 Key Points Although HIV/AIDS is found throughout the world, most people living with HIV/AIDS reside in low- and middle-income countries More people.
HIV 101 HIV/AIDS Program Public Health - Seattle & King County
Melbourne, 23 July IAS 2014 Fatiha Terki, WFP Critical enablers and synergies including nutrition.
Overview of HIV & AIDS in Africa
Module 1: Overview of HIV Infection. Lab workersHealth workersCounselors 2 Learning Objectives At the end of this module, you will be able to: Describe.
HIV/AIDS.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Home economics 9th grade – 4th partial
A generation of children free from AIDS is not impossible Children and AIDS Fourth Stocktaking Report, 2009.
The HIV/AIDS Epidemic © 2013 John B. Pryor Illinois State University.
UNAIDS Sharing Experiences from SA Workplace Wellness Dialogues Dr Miriam Chipimo Senior Policy & Programme Adviser SA BCOHA &ILO Pre-Conference Workshop.
Unit 3: Biology, Transmission, Natural History, Prevention and Treatment of HIV Infection and AIDS #1-3-1.
Chapter 21 Preview Bellringer Key Ideas What Are HIV and AIDS?
STIs/HIV/AIDS. ( 2 ) Sexually transmitted infections (STIs) are spread primarily through sexual contact and are among the most common diseases in the.
4. HIV/AIDS in Africa Takashi Yamano Development Issues in Africa Spring 2007.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
There are 2 predictions for the population of Botswana in what could cause a difference like this?
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
PMTCT Generic Training PackageModule 1Slide 1 Introduction to HIV/AIDS M O D U L E 1.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
A TRANSMITTABLE DISEASE AIDS. WHY AIDS? Geographers are concerned with the Geography of AIDS because it has not spread evenly throughout the world and.
Map of HIV Prevalence Worldwide
HIV and AIDS Data Hub for Asia-Pacific 11 HIV and AIDS Data Hub for Asia-Pacific Review in slides Mongolia.
Washington D.C., USA, July 2012www.aids2012.org Geeta Rao Gupta, Deputy Executive Director, UNICEF.
1 HIV / AIDS EPIDEMIC ININDIA Lt Col HS Ratti, MD (PSM), DNB.
1 HIV Prevention for Patients and the Community HAIVN Harvard Medical School AIDS Initiative in Vietnam.
00002-E-1 – 1 December 2002 The AIDS Pandemic: an Update on the Numbers and Needs l What are the numbers for 2002? l What are the global and regional trends?
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
Week 3: HIV/AIDS in Africa Takashi Yamano Development Problems in Africa Spring 2006.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
GLOBAL UNITED CHILDREN’S FOUNDATION, Inc Presents “Using Education to Contain the Spread of HIV/AIDS in Africa and Expand Treatment in Rural Communities.
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
What is HIV? HIV is a virus that takes over certain immune system cells to make many copies of itself. HIV causes slow but constant damage to the immune.
Home economics 9 th grade – 4 th partial. Sexual education is instruction on issues relating to human sexualityincluding:  human sexual anatomy  sexual.
Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.
10 facts about AIDS Source: World Health Organization
The Global HIV/AIDS Epidemic Jennifer Kates, M.A., M.P.A. Vice President and Director, HIV Policy Kaiser Family Foundation KaiserEDU.org Tutorial April.
Session: 3 The four pronged approach to comprehensive prevention of HIV in infants and young children Dr.Pushpalatha, Assistant Professor, Dept of Pediatrics,
HIV/AIDS IN AFRICA- "The Orphaned Continent"
25 Years of AIDS – The Global Response 16 August 2006 XVI International AIDS Conference Toronto.
Dan Dougherty and Allie Capetola Period 5.  Human immunodeficiency virus  Leads to AIDS (Acquired immunodeficiency syndrome)  HIV is spread through.
HIV AND AIDS IN SUB-SAHARAN AFRICA By: Matt, Tim, and Alana.
New Prevention Technologies Workshop Module 2: NPTs in context
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
Africans and HIV in the UK: an epidemiological perspective May 2006 Valerie Delpech On behalf of the HIV Reporting Section with special thanks to Julia.
HIV and AIDS Quiz ANSWERS A Strategic Planning Session for Parliamentary Select Committees on HIV/AIDS and the Social Cluster Portfolio Committee. Maseru,
Provider Initiated HIV Counseling and Testing Unit 1: Introduction to HIV/AIDS.
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities
The HIV Response Where are we now?
Number of people receiving antiretroviral therapy in
WHO strategy on HIV/AIDS “Getting to Zero”
27 years of responding to AIDS
Singapore Last updated: November 2016.
27 years of responding to AIDS
AIDS supplement.
"3 by 5" progress December 2005.
27 years of responding to AIDS
HIV/AIDS Surveillance in Europe 2011 HIV/AIDS Surveillance in Europe
Presentation transcript:

Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 7

Harvard University Initiative for Global Health Biology, Clinical Manifestations and Interventions Overview Viral Life Cycle Natural History of Disease Modes of Transmission Preventive Interventions Treatment Interventions Global Distribution and Trends in HIV The Unfolding Epidemic Sub-Saharan Africa Asia History of the Health System Response Challenges and Controversies Vaccines and Microbicides Prevention versus Treatment Scaling Up Societal Impact

Harvard University Initiative for Global Health HIV disease is characterized by a gradual decline in immune function. Crucial immune cells called CD4+ T cells are disabled and killed during the course of infection. Healthy uninfected individuals have CD4 cells per mm3 of blood. During HIV infection CD4 declines progressively. When CD4<200/mm3 the individual becomes afflicted by opportunistic infections and cancers. HIV Disease

Harvard University Initiative for Global HealthPrimaryinfectionAsymptomatic HIV infection SymptomaticHIV/AIDS Years Months Viral load ‘set point’ HIV-1 RNA CD4

Harvard University Initiative for Global Health Transmission is through sexual contact, blood contact (intravenous drug use, unsafe healthcare injections, unsafe blood transfusions) and maternal to child transmission. Probability of transmission per heterosexual coital act is 1/1000. Annual probability of transmission for a discordant heterosexual couple averaging 9 coital acts per month is 10.2%. Transmission probability increases as a function of viral load. Modes of Transmission

Harvard University Initiative for Global Health Probability as high as 8/1000 in early stage of infection. Male-to-female and female-to-male transmission probability where studied in Africa is equal Transmission probabilities are also a function of type of sex: much lower for oral sex, higher for anal sex, dry sex may increase risk Transmission Co-Factors

Harvard University Initiative for Global Health Presence of genital ulceration from other sexually transmitted diseases increases transmission probability by 2-4 times. Male circumcision probably reduces the probability of transmission from female to the male. Mother to child transmission without intervention is approximately 30%. Transmission Co-Factors

Harvard University Initiative for Global Health Change sexual behaviour (mass media, voluntary counseling and testing, peer-to-peer outreach, school, work and youth programmes: Promotion of abstinence Delayed sexual debut Decrease number of partners Decrease number of high-risk sexual contacts Change probability of transmission per coital act: Treatment of STDs – mixed trial results Male circumcision – 1 positive trial, 2 pending Promote condom use – Promote safer sexual practices - ?? Decrease transmission from mother to child – during delivery or through breastfeeding Antiretroviral prophylaxis for mother and child HIV Preventive Interventions

Harvard University Initiative for Global Health

Egger et al 2002, Lancet

Harvard University Initiative for Global Health Results of HAART in Treatment Naïve Patients, Europe and USA Egger et al 2002, Lancet

Harvard University Initiative for Global Health Biology, Clinical Manifestations and Interventions Overview Viral Life Cycle Natural History of Disease Modes of Transmission Preventive Interventions Treatment Interventions Global Distribution and Trends in HIV The Unfolding Epidemic Sub-Saharan Africa Asia History of the Health System Response Challenges and Controversies Vaccines and Microbicides Prevention versus Treatment Scaling Up Societal Impact

Harvard University Initiative for Global Health

Recent population-based blood surveys in developing countries suggest that prevalence from ANC clinics may be too high. True prevalence may be 30% lower than suggested by ANC data. Antenatal Clinic Sero-Surveillance and Population Sero-Surveys

Harvard University Initiative for Global Health HIV Sero-prevalence in Adults, 2005

Harvard University Initiative for Global Health HIV Sero-Prevalence 2005

Harvard University Initiative for Global Health

Uganda since 1992 has had a remarkable decline in sero-prevalence. Many, many analyses of this decline which claim different relative contributions of: delay of first sexual contact, decrease in the number of concurrent sexual partners (‘zero grazing campaign’), increase in condom use. ABC debate: A is for abstinence, B is for ‘be faithful’, and C is for condoms. Uganda

Harvard University Initiative for Global Health

Biology, Clinical Manifestations and Interventions Overview Viral Life Cycle Natural History of Disease Modes of Transmission Preventive Interventions Treatment Interventions Global Distribution and Trends in HIV The Unfolding Epidemic Sub-Saharan Africa Asia History of the Health System Response Challenges and Controversies Vaccines and Microbicides Prevention versus Treatment Scaling Up Societal Impact

Harvard University Initiative for Global Health WHO created the Global Programme on AIDS in the late 1980s In 1996, United Nations created a new agency to spearhead the global response to HIV. The main focus of efforts was on raising awareness of the epidemic and advocating for a comprehensive approach to prevention. Many countries were slow to recognize the magnitude of the epidemic. Global Response to HIV (1)

Harvard University Initiative for Global Health Success of ARVs in extending survival for HIV infected individuals in rich countries has increased international focus on HIV. Massive increase in sero-prevalence and rise in mortality in East and Southern Africa has made it impossible for politicians to ignore the epidemic. WTO Doha round of negotiations reflected developing country demands for access to effective medications. Global Response to HIV (2)

Harvard University Initiative for Global Health In 2001, Global Fund for AIDS, Tuberculosis and Malaria created to channel new resources to these three diseases. GFATM has disbursed more than $2 billion by end of In 2003, President Bush announced President’s Emergency Plan for AIDS Relief (PEPFAR), US$ 15 billion over 5 years. Global Response to HIV (3)

Harvard University Initiative for Global Health JW Lee took over as new Director-General of WHO July 21, His stated main priority is delivering ARVs to poor countries. This is a major shift from a focus on prevention to treatment. Slogan capturing this policy shift is 3 by 5. A target of 3 million individuals on ARVs by December Global Response to HIV (4)

Harvard University Initiative for Global Health Number of People on ARVs in Low and Middle- Income Countries

Harvard University Initiative for Global Health Percent Needing ARVs Who Receive Them

Harvard University Initiative for Global Health Biology, Clinical Manifestations and Interventions Overview Viral Life Cycle Natural History of Disease Modes of Transmission Preventive Interventions Treatment Interventions Global Distribution and Trends in HIV The Unfolding Epidemic Sub-Saharan Africa Asia History of the Health System Response Challenges and Controversies Vaccines and Microbicides Prevention versus Treatment Scaling Up Societal Impact

Harvard University Initiative for Global Health Two vaccine trials completed with no significant benefits. General pessimism on the prospects for a vaccine in the short to medium term. Interest in vaginal microbicides. Proponents argue that they would empower women in settings where they are unable to demand that male sexual partners use condoms. No effective microbicide has yet been through clinical trials (Phase III). Vaccines and Microbicides

Harvard University Initiative for Global Health Common debate in HIV policy is the balance of emphasis on prevention and treatment. Most commentators argue for a mixture of both; at issue is the emphasis on one or the other. To help clarify the debate, can consider two polar extremes: prevention first, treatment second vs treatment first, prevention second. Prevention vs Treatment

Harvard University Initiative for Global Health. Thailand used as model case. Proponents argue emphasis should be on preventing infection and then on providing ARVs to those who have been infected. Thailand used as model case. Criticisms: 1)failure of prevention programs in the majority of countries with large epidemics; 2) poor understanding of differences in sexual behaviour across different countries; and 3) weak evidence on the effectiveness of specific prevention programs. Prevention First, Treatment Second

Harvard University Initiative for Global Health emphasis should be on delivering ARVs to those who need them. Proponents argue emphasis should be on delivering ARVs to those who need them. Proposed benefits: 1) reduce mortality dramatically in the infected; 2) encourage voluntary testing and counseling for HIV infection which will lead to decreased transmission; 3) increase national commitment and resources to tackling HIV and thus increase spending on prevention programs as well; and 4) dramatically raise morale of health workers in beleaguered health systems improving their overall effectiveness Treatment First, Prevention Second

Harvard University Initiative for Global Health : 1) overriding emphasis on ARV treatment will suck dollars, health workers and energy out of prevention efforts and other priority health programs; Critics’ arguments: 1) overriding emphasis on ARV treatment will suck dollars, health workers and energy out of prevention efforts and other priority health programs; 2) emphasizing treatment can lead to increases in risky sexual behaviour and thus transmission of the virus; and 3) resources invested in ARVs will be wasted because most afflicted countries do not have the human resources and managerial infrastructure to effectively deliver a life long complex intervention. Treatment First, Prevention Second (2)

Harvard University Initiative for Global Health

Dramatic success of scaling up ARV programs in Sub-Saharan Africa to approximately 20% coverage. Challenges to further expansion especially outside of urban areas. Many PEPFAR funded programs use physicians and nurses, human resource shortages may limit this model. Successful models using community health workers have so far been local. Scaling Up